TY - JOUR
T1 - Higher risk of mismatch repair-deficient colorectal cancer in α1-antitrypsin deficiency carriers and cigarette smokers
AU - Yang, Ping
AU - Cunningham, Julie M.
AU - Halling, Kevin C.
AU - Lesnick, Timothy G.
AU - Burgart, Lawrence J.
AU - Wiegert, Elaine M.
AU - Christensen, Eric R.
AU - Lindor, Noralane M.
AU - Katzmann, Jerry A.
AU - Thibodeau, Stephen N.
N1 - Funding Information:
1This work was supported in part by Research Grants CA 68535, CA 77118, CA 62242, and AR 30592 from the National Institutes of Health, United States Public Health Service.
PY - 2000
Y1 - 2000
N2 - Microsatellite instability (MSI) is a genomic alteration observed in 15-30% of colorectal cancer (CRC). Two MSI phenotypes have been defined for CRC: MSI-H is characterized by MSI at ≥30% of the examined loci and MSI-L by MSI at 1-30% of the loci. An absence of MSI at any examined loci has been defined as a microsatellite stable (MSS) phenotype. Current data suggest the majority of MSI tumors are the result of defective DNA mismatch repair (MMR). In this study, we have determined the α1-antitrypsin deficiency carrier (α1ATD-ht) status of 161 CRC patients whose MSI phenotype and protein expression states had previously been determined. Cases were selected to enrich a larger number of MSI-H cases. Among 51 CRC patients with MSI-H tumors, the α1ATD-ht rate was 21.6%; among 110 patients with MSI-L/MSS tumors, the rate was 9.1% (MSI-H vs MSI-L/MSS. P = 0.02): and among the 191 population-based controls the α1ATD-ht rate was 9.4.% (MSI-H vs controls, P = 0.02). The estimated relative risk of having MSI-H CRC among α1ATD-ht was 3.1 after adjusting for age, gender, and smoking history. The risk of having MSI-H CRC among current and past smokers was 6.6 and 2,7, respectively. Patients who were α1ATD-ht and smoked had a 20-fold increased risk of developing an MSI-H CRC compared to nonsmokers who were homozygous normal at the α1ATD locus. Our findings suggest an etiologic link between α1ATD alleles and development of CRC with defective MMR, and a synergistic effect between smoking and α1ATD allele in the development of MSI-H CRC.
AB - Microsatellite instability (MSI) is a genomic alteration observed in 15-30% of colorectal cancer (CRC). Two MSI phenotypes have been defined for CRC: MSI-H is characterized by MSI at ≥30% of the examined loci and MSI-L by MSI at 1-30% of the loci. An absence of MSI at any examined loci has been defined as a microsatellite stable (MSS) phenotype. Current data suggest the majority of MSI tumors are the result of defective DNA mismatch repair (MMR). In this study, we have determined the α1-antitrypsin deficiency carrier (α1ATD-ht) status of 161 CRC patients whose MSI phenotype and protein expression states had previously been determined. Cases were selected to enrich a larger number of MSI-H cases. Among 51 CRC patients with MSI-H tumors, the α1ATD-ht rate was 21.6%; among 110 patients with MSI-L/MSS tumors, the rate was 9.1% (MSI-H vs MSI-L/MSS. P = 0.02): and among the 191 population-based controls the α1ATD-ht rate was 9.4.% (MSI-H vs controls, P = 0.02). The estimated relative risk of having MSI-H CRC among α1ATD-ht was 3.1 after adjusting for age, gender, and smoking history. The risk of having MSI-H CRC among current and past smokers was 6.6 and 2,7, respectively. Patients who were α1ATD-ht and smoked had a 20-fold increased risk of developing an MSI-H CRC compared to nonsmokers who were homozygous normal at the α1ATD locus. Our findings suggest an etiologic link between α1ATD alleles and development of CRC with defective MMR, and a synergistic effect between smoking and α1ATD allele in the development of MSI-H CRC.
KW - Case-control study
KW - Cigarette smoking
KW - Colorectal cancer
KW - Microsatellite instability
KW - Mismatch repair
KW - α-antitrypsin deficiency
UR - http://www.scopus.com/inward/record.url?scp=0034524177&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034524177&partnerID=8YFLogxK
U2 - 10.1006/mgme.2000.3089
DO - 10.1006/mgme.2000.3089
M3 - Article
C2 - 11136557
AN - SCOPUS:0034524177
SN - 1096-7192
VL - 71
SP - 639
EP - 645
JO - Biochemical Medicine and Metabolic Biology
JF - Biochemical Medicine and Metabolic Biology
IS - 4
ER -